drugset / Trial / NCT06345300
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Phase 2
Unknown
40 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the efficacy and safety of Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab for patients with borderline resectable pancreatic cancer
Timeline
- Start
- 2024-03-10
- Primary completion
- 2024-12-12
- Completion
- 2025-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Calcium folinate | Unknown | 400 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 60 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |